| This week's sponsor is Navitas. | | | |
Top Stories Tuesday, July 19, 2016 An FDA advisory committee recommended that the agency approve Valeant’s brodalumab to treat moderate-to-severe plaque psoriasis. But it also advised that the biopharma implement additional risk-management options for suicidal ideation--which had proved to be a problem in Phase III testing. Tuesday, July 19, 2016 Zafgen fell about 40% in after-hours trading on news that it has suspended development of its lead obesity candidate beloranib, which had been on a clinical hold since December, to get its follow-on candidate into clinical testing. Wednesday, July 20, 2016 The Cambridge, MA-based startup Amylyx Pharmaceuticals has been given charity backing to run its first in-human clinical trial for its oral, combination ALS candidate AMX0035. Wednesday, July 20, 2016 Troubled Canadian specialty pharma company Valeant has won U.S. approval for a new, oral formulation of the previously injectable-only med Relistor for certain forms of constipation in what could push the drug into blockbuster territory. Wednesday, July 20, 2016 California-based synthetic biology player Synthorx has raised $10 million in a Series B round as it looks to bring what it sees as its “ground-breaking technology” into the clinic. | | | New York’s Immune Pharmaceuticals has announced it will form a pain and neurology spinoff company around the AmiKet IP. Statement Zafgen and Genzyme veteran Alicia Secor has become the new president and CEO of Boston women’s health company Juniper Pharmaceuticals. Release AstraZeneca has announced that the European Commission has approved Qtern (saxagliptin/dapagliflozin) tablets for the treatment of Type 2 diabetes. Statement Cambridge, MA-based Sarepta has reported a net loss of $62.3 million, or $1.35 per share, compared to a net loss of $41.9 million for Q2 of last year. Release | |
|
Resources Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. This series provides an overview of the science and technology used to enable discovery and the processes scientists use to discover new therapeutics. Download now. Sponsored by: Speid & Associates, Inc. Do you have what it takes? Drug Development training does not have to be boring. The Drug Development Boot CampTM trains experienced researchers and drug developers in all major aspects of drug development, using an accelerated learning and total immersion approach. Click here to website. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. BIOSPAIN 2016 September 28-30, 2016 | Bilbao, Basque Country, Spain FierceBiotech Drug Development Forum September 19-21, 2016 | Boston, MA Immunotherapy: Mapping the future July 28, 2016 | Foster City, CA BioImmersion: In Depth Biotech for the Non-Scientist October 5-7, 2016 | Chicago, IL Drug Development Boot CampTM 2016 November 16-17, 2016 | Boston, MA Characterization of Animal Models for Alzheimer’s disease: Webinar Presented by Charles River July 19, 2016 Master of Science in Bioinformatics at Northeastern University Fall 2016, Spring 2017 Courses |
